Literature DB >> 9202932

Mechanisms of actions of opioids and non-steroidal anti-inflammatory drugs.

J G Bovill1.   

Abstract

Opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are the commonest drugs used to treat pain. Opioids mimic the actions of endogenous opioid peptides by interacting with mu, delta or kappa opioid receptors. The opioid receptors are coupled to G1 proteins and the actions of the opioids are mainly inhibitory. They close N-type voltage-operated calcium channels and open calcium-dependent inwardly-rectifying potassium channels. This results in hyperpolarization and a reduction in neuronal excitability. They also decrease intracellular cAMP which modulates the release of nociceptive neurotransmitters (e.g. substance P). Inhibition of prostaglandin synthesis by cyclooxygenase is the principal mode of the analgesic and anti-inflammatory actions of NSAIDs. Cyclo-oxygenase is inhibited irreversibly by aspirin and reversibly by other NSAIDs. The widespread inhibition of cyclo-oxygenase is responsible for many of the adverse effects of these drugs. NSAIDs also reduce prostaglandin production within the CNS. This is the main action of paracetamol.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9202932     DOI: 10.1097/00003643-199705001-00003

Source DB:  PubMed          Journal:  Eur J Anaesthesiol Suppl        ISSN: 0952-1941


  21 in total

Review 1.  Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit.

Authors:  Adeleke D Adewumi; Christine E Staatz; Samantha A Hollingworth; Jason P Connor; Rosa Alati
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

2.  Activation of CXCL10/CXCR3 signaling attenuates morphine analgesia: involvement of Gi protein.

Authors:  Dawei Ye; Huilian Bu; Genhua Guo; Bin Shu; Wei Wang; Xuehai Guan; Hui Yang; Xuebi Tian; Hongbing Xiang; Feng Gao
Journal:  J Mol Neurosci       Date:  2014-01-12       Impact factor: 3.444

3.  Updated Review of Fish Analgesia.

Authors:  Frederic Chatigny; Catherine M Creighton; E Don Stevens
Journal:  J Am Assoc Lab Anim Sci       Date:  2018-01-01       Impact factor: 1.232

4.  COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.

Authors:  N V Chandrasekharan; Hu Dai; K Lamar Turepu Roos; Nathan K Evanson; Joshua Tomsik; Terry S Elton; Daniel L Simmons
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

5.  Characterization of opioid receptors that modulate nociceptive neurotransmission in the trigeminocervical complex.

Authors:  R J Storer; S Akerman; P J Goadsby
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

6.  Analgesic Effects of Danggui-Shaoyao-San on Various "Phenotypes" of Nociception and Inflammation in a Formalin Pain Model.

Authors:  Jun-Bin Yin; Ke-Cheng Zhou; Huang-Hui Wu; Wei Hu; Tan Ding; Ting Zhang; Li-Ying Wang; Jun-Ping Kou; Alan David Kaye; Wen Wang
Journal:  Mol Neurobiol       Date:  2015-12-12       Impact factor: 5.590

7.  Synergistic analgesia of duloxetine and celecoxib in the mouse formalin test: a combination analysis.

Authors:  Yong-Hai Sun; Yu-Lin Dong; Yu-Tong Wang; Guo-Li Zhao; Gui-Jun Lu; Jing Yang; Sheng-Xi Wu; Ze-Xu Gu; Wen Wang
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

8.  The effect of adjuvant midazolam compared with fentanyl on the duration of spinal anesthesia with 0.5% bupivacaine in opium abusers.

Authors:  Farhad Safari; Ali Dabbagh; Mansour Sharifnia
Journal:  Korean J Anesthesiol       Date:  2012-12-14

9.  Comparison of the pattern, efficacy, and tolerability of self-medicated drugs in primary dysmenorrhea: a questionnaire based survey.

Authors:  Ramya Sugumar; Vasundara Krishnaiah; Gokul Shetty Channaveera; Shilpa Mruthyunjaya
Journal:  Indian J Pharmacol       Date:  2013 Mar-Apr       Impact factor: 1.200

10.  Isolation of Bioactive Compounds That Relate to the Anti-Platelet Activity of Cymbopogon ambiguus.

Authors:  I Darren Grice; Kelly L Rogers; Lyn R Griffiths
Journal:  Evid Based Complement Alternat Med       Date:  2011-02-14       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.